- Recruiting
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
Sponsor
ClinicalTrials.gov Identifier: NCT04960579
Official Title: Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
First Posted : July 14, 2021
Click here for details on Clinicaltrials.gov
Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1
Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1 (Code C181747)
Allogeneic Anti-BCMA CAR T Cells P-BCMA-ALLO1
Allogeneic Anti-BCMA-CAR-expressing Tscm P-BCMA-ALLO1
Allogeneic Tscm-rich Anti-BCMA CAR T Cells P-BCMA-ALLO1
P-BCMA-ALLO 1
P-BCMA-ALLO-1
P-BCMA-ALLO1
Biological: P-BCMA-ALLO1 CAR-T cells
Drug: Rimiducid
3858 Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster III
Hematology Disease Topics & Pathways:
Biological therapies, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Therapies
Monday, December 13, 2021, 6:00 PM-8:00 PM
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported interim results from its Phase 1/2 PRIME clinical trial of P-BCMA-101 for the treatment of relapsed/refractory multiple myeloma (R/R MM) at the 2021 American Society of Hematology (ASH) Annual Meeting.
Locations
United States, California
United States, Illinois
United States, Maryland
United States, Oklahoma
United States, Texas